VivoSeq
Other

DMD

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

DMD is an early-stage landscape with 0 programs across 5 companies. The most active players are Sarepta Therapeutics, BioMarin Pharmaceutical, Processa Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sarepta Therapeutics logo

Sarepta Therapeutics

0 programs

PreclinicalBioMarin Pharmaceutical logo

BioMarin Pharmaceutical

0 programs

PreclinicalP

Processa Pharmaceuticals

0 programs

PreclinicalA

Akashi Therapeutics

0 programs

PreclinicalNS Pharma logo

NS Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Terminated3 · 30%
Active, not recruiting1 · 10%
No longer available1 · 10%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

NS-050/NCNP-03 in Boys With DMD (Meteor50)
Recruiting·NS Pharma logoNS Pharma·Phase 1/2·NCT06053814·20 enrolled
Extension Study of NS-089/NCNP-02 in DMD
Active, not recruiting·NNippon Shinyaku Co., Ltd.·Phase 2·NCT05135663·6 enrolled
Exploratory Study of NS-065/NCNP-01 in DMD
Completed·NNational Center of Neurology and Psychiatry, Japan·Phase 1·NCT02081625·10 enrolled
Study of Eteplirsen in DMD Patients
Completed·Sarepta Therapeutics logoSarepta Therapeutics·Phase 3·NCT02255552·109 enrolled
Exploratory Study of NS-089/NCNP-02 in DMD
Completed·NNational Center of Neurology and Psychiatry, Japan·Phase 1/2·NCT04129294·6 enrolled
Phase I/II Study of SRP-4053 in DMD Patients
Completed·Sarepta Therapeutics logoSarepta Therapeutics·Phase 1/2·NCT02310906·39 enrolled
CoQ10 and Prednisone in Non-Ambulatory DMD
Terminated·CCooperative International Neuromuscular Research Group·Phase 3·NCT00308113·3 enrolled
Open Label Extension Study of HT-100 in Patients With DMD
Terminated·PProcessa Pharmaceuticals·Phase 2·NCT01978366·17 enrolled
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02
Terminated·AAkashi Therapeutics·Phase 2·NCT02525302·10 enrolled
Extension Study of Drisapersen in DMD Subjects
No longer available·BioMarin Pharmaceutical logoBioMarin Pharmaceutical·N/A·NCT02636686

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)